Navigation Links
Frost & Sullivan Lauds Toscana Biomarkers' Outstanding Contributions to the R&D of Novel Biomarkers for the Diagnosis of Autoimmune Diseases
Date:1/13/2009

LONDON, Jan. 13 /PRNewswire/ -- Based on its recent analysis of the autoimmune disease diagnostics markets, Frost & Sullivan recognizes Toscana Biomarkers with the 2008 European Frost & Sullivan Excellence in Research Award. The company demonstrated that the incorporation of synthetically modified peptides for the validation and discovery of biomarkers aids effective diagnosis of autoimmune diseases and is also looking to adopt robust methods to identify novel diagnostic solutions.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Biomarkers have been used extensively in the genetic and molecular analysis of complications such as autoimmune diseases. Toscana Biomarkers focuses on identifying specific biomarkers detectable in patients' serum samples and validating the same with respect to the disease progression and activity.

"Antigenic peptides that can selectively and specifically recognise autoantibodies can be used in immunoenzymatic assays to detect disease biomarkers," says Frost & Sullivan Research Analyst Suraj Ramanathan. "Therefore, the company aims to develop robust biomarkers panel for the diagnosis of autoimmune diseases ranging from rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) to more complex diseases such as multiple sclerosis (MS) and systemic sclerosis."

To complement its focus on the manufacture of novel disease biomarkers, Toscana Biomarkers is working on developing in-vitro diagnostic assays, especially the enzyme-linked immuno sorbent assay (ELISA) for autoimmune diseases.

The company's R&D revolves around a peptide-based reverse approach [chemical reverse approach (CRA)], which indicates that the screening of antigenic probes is primarily guided by the antibodies circulating in a patient's biological fluids. The circulating auto-a
'/>"/>

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Frost & Sullivan Lauds SonoScapes Outstanding Entrepreneurship
2. Frost & Sullivan Awards Toshiba America Medical Systems for Innovation in Cardiovascular Imaging Products and Services
3. Frost & Sullivan Awards SourceOne Global Partners for Proprietary Heart Health Formulas
4. Excellence in Supply Chain and Manufacturing Recognized at Frost & Sullivans India Manufacturing Excellence Awards 2008
5. Frost & Sullivan Recognises Best-in-Class Innovators
6. Ansell Healthcare Europe Lands 2008 Frost & Sullivan Customer Service Leadership Award for its Ansell Guardian(SM) Safety Program
7. Frost & Sullivan Lauds StatCom for Its Hospital Operations System
8. Gencor Pacific Group Picks Up Frost & Sullivan Global Appetite Suppressant and Satiety Ingredients Product Innovation of the Year Award
9. Frost & Sullivan Honours GELITA for Developing European Health Ingredient of the Year
10. Healthcare Pioneer Dr. Ralph Snyderman to Receive Frost & Sullivans Lifetime Achievement Award
11. Frost & Sullivan to Present the 2008 Excellence in Healthcare Innovation Awards
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 1YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 2YAI NIPD Board of Trustees Elects Eliot Green Chair and Sheldon Kwiat Vice Chair 51695 3OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 1OH2 Medical Spa Achieves the First U S LEED 28R 29 Certification for a Medical Commercial Interior 51691 2Fitness Might Limit Strokes Impact 51687 1Fitness Might Limit Strokes Impact 51687 2